Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC): Supporting the transition from strategy to action. by Fukuda, Keiji et al.
Fukuda, K; Limmathurotsakul, D; Okeke, IN; Shetty, N; van Doorn,
R; Feasey, NA; Chiara, F; Zoubiane, G; Jinks, T; Parkhill, J; Patel, J;
Reid, SWJ; Holmes, AH; Peacock, SJ; Surveillance and Epidemiology
of Drug Resistant Infections Conso, (2018) Surveillance and Epidemi-
ology of Drug Resistant Infections Consortium (SEDRIC): Support-
ing the transition from strategy to action. Wellcome open research, 3.




Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
 Open Peer Review
OPEN LETTER
   Surveillance and Epidemiology of Drug Resistant Infections
Consortium (SEDRIC): Supporting the transition from strategy to
 action [version 2; referees: 2 approved, 1 approved with
reservations]
Keiji Fukuda ,       Direk Limmathurotsakul , Iruka N. Okeke , Nandini Shetty ,
       Rogier van Doorn , Nicholas A. Feasey , Francesca Chiara , Ghada Zoubiane ,

































1 2 3 4
5 6 7 7





























 16 May 2018,  :59 (doi:  )First published: 3 10.12688/wellcomeopenres.14586.1
 27 Jun 2018,  :59 (doi:  )Latest published: 3 10.12688/wellcomeopenres.14586.2
v2
Page 1 of 11









 Sharon J. Peacock ( )Corresponding author: sharon.peacock@lshtm.ac.uk
  : Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing – Original DraftAuthor roles: Fukuda K Limmathurotsakul D
Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing – OriginalOkeke IN Shetty N
Draft Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing –van Doorn R Feasey NA
Original Draft Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing;  :Chiara F Zoubiane G
Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing; Jinks T Parkhill J
: Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing; Patel J Reid
: Writing – Original Draft Preparation, Writing – Review & Editing;  : Writing – Original Draft Preparation, Writing – Review & Editing;SWJ Holmes AH
: Writing – Original Draft Preparation, Writing – Review & Editing;Peacock SJ
 No competing interests were disclosed.Competing interests:
 Fukuda K, Limmathurotsakul D, Okeke IN   How to cite this article: et al. Surveillance and Epidemiology of Drug Resistant Infections
Consortium (SEDRIC): Supporting the transition from strategy to action [version 2; referees: 2 approved, 1 approved with
 Wellcome Open Research 2018,  :59 (doi:  )reservations] 3 10.12688/wellcomeopenres.14586.2
 © 2018 Fukuda K  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 This work is supported by the Wellcome Drug Resistant Infection Priority Programme.Grant information:
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.









Page 2 of 11
Wellcome Open Research 2018, 3:59 Last updated: 05 JUL 2018
Introduction
The discovery, production and global use of antimicrobial drugs 
represents one of the most important achievements in medical 
history, and has contributed significantly to a major increase in 
life expectancy. Antimicrobial drugs continue to safeguard 
millions of lives each year, and ensuring access to quality 
medicines is key to continued gains in global health and devel-
opment. However, widespread use of antimicrobials in humans, 
livestock and agriculture for health and non-health purposes 
in the 70 years since their commercial production has acceler-
ated the emergence of drug-resistant lineages for the majority 
of common human pathogens worldwide.
The emergence and spread of antimicrobial resistance in the 
face of their extensive antibiotic use was both inevitable and 
predictable for rapidly replicating organisms like bacteria. This 
is based on the knowledge that bacteria develop antimicro-
bial agents to compete with other microorganisms in the natural 
environment, and therefore produce and use various resistance 
mechanisms to defend themselves. Genes encoding bacterial 
resistance to β-lactam,  tetracycline and glycopeptide drugs have 
been found in ancient DNA from 30,000-year-old Beringian 
permafrost sediments1. Humans who have never been treated 
with antimicrobial drugs are also colonised with bacteria that 
carry resistance genes, as shown by a study that detected a total 
of 28 different functional resistance genes in the microbiome of 
uncontacted Amerindians2.
A major response to rising rates of bacterial resistance has been 
to develop new drug classes. Although a successful and neces-
sary short-term strategy, this approach has inevitably selected 
new resistance patterns. Antimicrobial drug discovery itself 
has faltered as the string of easy wins for developing new drugs 
was exhausted and many pharmaceutical companies withdrew 
from their discovery3. The combination of rising rates of bacte-
rial resistance to commonly used antimicrobial drugs, their con-
tinued widespread and uncontrolled use and the lack of new 
therapeutic agents represents the perfect storm. Over the last 
5 or so years there has been an increasing realisation of 
the scale of the global societal threat posed to human and 
animal health, agriculture, food and economic development. One 
of the pillars for sustainably reducing antimicrobial resistance 
worldwide is the need to measure and monitor resistance using 
appropriate surveillance systems.
A new and broader social and political awareness is now gath-
ering pace. This has been reflected in the G20 summit of 2016 
where leaders acknowledged the gravity of the threat and the 
need to stimulate new drug discovery and pursue interna-
tional discussions; the launch of a global action plan to tackle 
antimicrobial resistance at the World Health Assembly in 2015; and 
the United Nations High Level Meeting on antimicrobial resist-
ance and a General Assembly declaration in 2016 endorsing the 
plan and committing to take action. Aligned with this, the World 
Health Organization (WHO), Food and Agriculture Organization 
(FAO) and World Organization for Animal Health (OIE) have 
encouraged and supported countries to develop national action 
plans. The WHO has also developed a Global Antimicrobial 
Resistance Surveillance System (GLASS) to collect and report 
data on antimicrobial resistance rates aggregated at the national 
level and to develop international standards for surveillance 
to support stepwise participation by Member States over time4.
At the same time, a firm long-term commitment to address 
antimicrobial resistance cannot be considered assured until 
this high level political strategy is translated into action across 
multiple sectors. The problem of antimicrobial resistance is 
acknowledged as being immensely complex. Nonetheless, 
clarity is being increasingly provided by numerous organiza-
tions, and several recent reviews5–7. Common themes include 
the need for a stronger discovery pipeline for new antimicrobial 
drugs and alternatives such as vaccines; the development of new 
point-of-care diagnostics; increased stewardship through the 
appropriate therapeutic use of antimicrobial drugs in humans and 
veterinary medicine; and the prevention of infections. Surveil-
lance and epidemiology are widely recognised as critical cross-
cutting foundational activities, and include mapping patterns of 
infection (including non-resistant infection) and the rates of drug 
resistant infections over time for a range of bug-drug combina-
tions; estimation of the global economic, health and agricultural 
burden from drug resistant infections; mapping of the quality 
and quantity of antimicrobial drugs used in humans, animals and 
agriculture; the use and opportunity for better infection preven-
tion and control, including vaccine coverage for the prevention 
of infectious diseases; and reduced contamination of the envi-
ronment through better disposal practices and systems. The ideal 
surveillance system would integrate, or at the very least har-
monize monitoring across the totality of the ecosystem – hosts, 
environment and putative routes of dissemination. Although 
significant efforts have been made to develop global antimi-
crobial resistance-related surveillance systems, current health, 
agriculture, veterinary and environmental approaches are 
fragmented and poorly coordinated, which limits their value. For 
harmonized surveillance to occur across sectors and countries, 
leadership by major international organizations and agreement 
across sectors to address and find ways to minimize differences 
among methodologies will be needed.
SEDRIC
In recognition of the central importance of surveillance and 
epidemiology in the control of antimicrobial resistance and the 
need to strengthen and harmonize surveillance from local to 
global levels and across multiple sectors, especially health, 
agriculture and the environment, Wellcome has brought together 
a new international expert group termed SEDRIC (Surveillance 
and Epidemiology of Drug Resistant Infections Consortium)8. 
SEDRIC aims to advance and where needed transform the 
ways that the global community are able to track, share and 
analyse information on antimicrobial use, together with rates of 
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antimicrobial resistance and burden of disease and costs and, 
importantly, contamination of the environment. Its goal is to 
strengthen the availability of information needed to monitor 
and track risks, and to support the translation of surveillance 
data into interventions, changes in policy and more effective 
practices. Crucially, SEDRIC will have a particular focus on 
defining gaps in data and knowledge and barriers to the delivery 
of global surveillance functions, and on finding solutions to 
support existing systems such the WHO GLASS. Further 
details describing SEDRIC are summarised in Table 1.
The SEDRIC Board, which oversees the Consortium, includes 
11 experts with extensive experience in human and veterinary 
health, drug-resistant infections and infectious pathogens and 
diseases more generally, including human and veterinary health, 
infection control and antimicrobial stewardship, laboratory 
microbiology, epidemiology, genomics, modelling, implemen-
tation and delivery of surveillance, and policy making. This 
group will be complemented by a wider network of members 
who are willing to contribute to the activities undertaken by 
SEDRIC, including the development and writing of reviews 
and opinion pieces, working groups, and commissioned work.
At the first SEDRIC Board meeting in January 2018, gaps and 
barriers to effective surveillance were identified and prioritised. 
The single most important short-term problem identified by 
these discussions was related to the need to intensify the gen-
eration, collection, collation and dissemination of high quality 
epidemiological data, together with the need for more creativ-
ity in the use of existing data and proxy measures, and linking to 
existing in-country capabilities. The collection of data across 
multiple sectors in a way that is useful, complementary 
and harmonized is a formidable challenge. Related issues 
include consideration of the optimal amount and frequency of 
data collection; standardised definitions and harmonised data 
collection methodology to permit comparability of findings; and 
the strengths and weaknesses of existing data collection tools, 
including their capacity for generalisability across a range of 
settings and levels of infrastructure. For example, an issue is 
how to relate patient outcome from bacterial infection data. A 
SEDRIC working group has been formed to further evaluate gaps 
and challenges relating to data and report on its findings and 
recommendations.
Allied to this data theme is consideration of how to iden-
tify, access and use available data from multiple sources. For 
example, large volumes of bacterial susceptibility data to 
numerous antimicrobial drugs are generated by pharmaceu-
tical companies to fulfil regulatory requirements. Extensive 
information is also generated through research. Many of these 
data are likely to be of high quality but are generally not being 
utilized for surveillance purposes. In low and middle-income 
countries (LMIC), available quality-assured data originates 
mainly from individual research projects in well-funded 
academic institutions or the private sector9. Where other sources 
of surveillance information are currently limited, use of data 
from such sources could be of considerable benefit. Whilst it is 
widely acknowledged that developing a reliance on data gener-
ated by research or from the private sector has its drawbacks in 
terms of generalisability and sustainability, ignoring such data is 
also unwise. Such data could provide significant information in 
the interim to countries that are actively working towards capacity 
building and training in critical areas such as microbiology. 
A SEDRIC-led paper to be published in the coming months will 
discuss this in more detail.
SEDRIC will also promote the translation of technological 
innovations into public health solutions in alignment with 
Wellcome’s goal to support and facilitate the rapid advance-
ment of discoveries into improving health globally. For example, 
innovations could significantly enhance surveillance of drug 
resistant infections. This includes the development and wide-
spread use of new laboratory instruments that are robust, simple 
to use and provide accurate bacterial identification and testing of 
Table 1. SEDRIC explained.
What is SEDRIC? An international consortium of experts in the surveillance and epidemiology of drug resistant infections, and 
pathogens and infectious diseases more generally. A Board provides oversight and there is an inclusive 
membership of individual and institutional members.
Why was it created? In recognition of the central importance of surveillance and epidemiology in the global effort to reduce drug 
resistant infections, and the need to strengthen surveillance at all levels from local to global and across multiple 
sectors including health, agriculture and the environment.
What is its purpose? To strengthen the availability of information needed to monitor and track risks, and to support the translation of 
surveillance data into interventions, changes in policy and more effective practices.
How will it work? SEDRIC will inform, influence and facilitate. Activities include a review series to highlight key challenges and 
actions to tackle this; working groups to undertake more detailed analyses of gaps, barriers and solutions; and 
an annual event for SEDRIC members to highlight activities, output and on-going priorities. 
Excluded activities SEDRIC is not a source of grant funding, and does not manage any aspect of research proposals.
Who can become 
an individual 
member?
People with expertise in any aspect of the surveillance and epidemiology of drug resistant infections or infectious 
disease more generally who will actively contribute to SEDRIC, including (but not limited to) the development and 
writing of reviews and opinion pieces, working groups, and commissioned work. 
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their susceptibility; the development of data capture tools 
using easier and enhanced connectivity including innovative 
data interfaces that are designed to reflect end-user inputs and 
experience; and the application of Artificial Intelligence 
methodologies. Such approaches can also be applied to captur-
ing trends in antimicrobial use and overall patterns of infec-
tious diseases. SEDRIC is particularly interested in ‘leapfrog’ 
technologies, especially those that are suitable and accessible 
for LMIC settings. SEDRIC will specifically consider the role of 
pathogen genome sequencing as an integral component of sur-
veillance and epidemiology. Such data can contribute to a more 
accurate and complete picture of the global emergence and 
spread of pathogens, identify the genetic basis for phenotypic 
resistance, and track novel resistance mechanisms as they 
emerge. Numerous research groups and some national surveil-
lance programmes are actively engaged in sequencing bacterial 
collections from around the world, but efforts are largely 
fragmented and data are generally not combined, limiting their 
use. Most broadly, SEDRIC will support and advocate for the 
translation of data into interventions and policy changes. 
Such outcomes are critical for “pulling” along transformation, 
change and increasing willingness to coordinate efforts. It is 
crucial that data from GLASS and multiple surveillance sources 
are critically analysed and translated into actions at both 
country and global levels at a pace that moves faster than the 
development of antimicrobial resistance and brings benefit to 
health.
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totality of the ecosystem – hosts, environment and putative routes of dissemination. Although
significant efforts have been made to develop global antimicrobial resistance-related surveillance
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 significant efforts have been made to develop global antimicrobial resistance-related surveillance
systems, current health, agriculture, veterinary and environmental approaches are fragmented and
poorly coordinated, which limits their value. For harmonized surveillance to occur across sectors
and countries, leadership by major international organizations and agreement across sectors to
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